IGF-LR3

IGF-1 LR3 (Long arginine 3-IGF-1) is a synthetic analog of insulin-like growth factor 1 (IGF-1) with modifications that extend its half-life and reduce binding to IGF-binding proteins. The "Long R3" designation refers to a 13-amino acid N-terminal extension and an arginine substitution at position 3, resulting in approximately 2-3 times longer biological activity than native IGF-1. [1][2]

Unlike endogenous IGF-1, which is largely bound to carrier proteins in circulation, IGF-1 LR3 exhibits reduced affinity for IGF-binding proteins, allowing greater bioavailability and tissue penetration. This structural modification enhances its anabolic and metabolic effects while extending its plasma half-life from minutes to several hours. [3]

Important Note: IGF-1 LR3 is NOT approved by regulatory agencies like the FDA for human use. It remains a research chemical used primarily in laboratory settings and animal studies. Its use in humans is experimental and potentially dangerous. [4][5]

Research-Observed Effects (Not Clinical Benefits):

Anabolic Activity:

• Enhanced protein synthesis in research models [1]
• Increased muscle cell proliferation and differentiation [2]
• Promotes nitrogen retention [3]
• Extended biological activity compared to native IGF-1 [4]

Metabolic Effects in Studies:

• Improved glucose uptake in muscle cells [5]
• Enhanced lipid metabolism in animal models [6]
• Increased metabolic rate [7]

Research Applications:

• Used in cell culture and tissue engineering studies [8]
• Animal model research for growth disorders [2]
• Metabolic research in laboratory settings [5]

WARNING: These are research observations, not established clinical benefits. IGF-1 LR3 is not approved for human therapeutic use and should not be used outside of controlled research settings. [4]

CRITICAL SAFETY WARNINGS:

Regulatory Status:

• NOT FDA-approved for human use [1]
• Classified as a research chemical only [2]
• Prohibited by WADA (World Anti-Doping Agency) [3]
• No established safe dosing in humans [4]

Potential Serious Risks:

• Cancer Risk: IGF-1 promotes cell proliferation and may increase cancer risk, particularly for existing tumors [5][6]
• Hypoglycemia: Can cause dangerously low blood sugar levels [7]
• Organ Enlargement: Risk of acromegaly-like symptoms (jaw, hands, feet growth) [8]
• Cardiovascular Effects: Potential for cardiac hypertrophy and arrhythmias [9]

Documented Adverse Effects in Research:

• Severe hypoglycemia requiring medical intervention
• Possible promotion of tumor growth
• Insulin resistance with prolonged use
• Joint pain and swelling
• Numbness and tingling
• Edema and water retention [5][10]

Contraindications:

• Active cancer or history of cancer
• Diabetic retinopathy
• Cardiovascular disease
• Any form of tumor or abnormal growth [6]

Drug Interactions:

• Insulin and diabetes medications (severe hypoglycemia risk)
• Growth hormone and other anabolic agents
• Medications affecting blood glucose [7]

Critical Notes:

• No quality control or purity standards for commercial products
• Long-term effects unknown
• No established reversal protocols for adverse effects
• Use constitutes human experimentation [4][11]

This compound should ONLY be used in approved research settings under proper scientific oversight. Self-administration is dangerous and illegal in many jurisdictions. [1][2]